UBS raised the firm’s price target on ResMed to $195 from $180 and keeps a Neutral rating on the shares. The firm notes ResMed reported a 10% beat to core EPS. Operating leverage, mainly via gross margin, has finally started to emerge, UBS adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
